Princeton, New Jersey -- Pharmaceutical company Agile Therapeutics has received $23.7 million in new venture capital investment, according to an SEC regulatory filing.
Agile is developing contraceptive pharmaceutical products that utilize its proprietary transdermal drug delivery technology.
Investors in the round were not disclosed, nor was how the company intends to use the funding proceeds.
Agile is still seeking $17 million in additional financing, according to the filing. |